David Grossman - D Pharm Chairman of the Board

  Chairman
Mr. David Grossman was appointed Chief Executive Officer at D Pharm Ltd effective November 2, 2016. This role is in addition to his role as Chairman of the Board at the Company, which he holds since September 6, 2016. He holds and has held Directorship at a variety of biotechnology companies. He holds a Bachelor of Business Administration degree, majoring in Information Technology, from The Interdisciplinary Center Herzliya.
Age: 40  Chairman Since 2016      
972 8 938 5100  http://www.dpharm.com

Management Efficiency

The company has return on total asset (ROA) of (42.09) % which means that it has lost $42.09 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (400.0) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 317K in total debt with debt to equity ratio (D/E) of 45.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. D Pharm LTD has Current Ratio of 1.51 which is within standard range for the sector.

Similar Executives

Found 7 records

CHAIRMAN Since

Paul SekhriCompugen Ltd
2017
Martin GerstelCompugen Ltd
2010
Ilan CohenCan Fite BioPharma Ltd
2013
John WaymackKitov Pharma Ltd
2013
Yitzhak SultanSolegreen Ltd
2014
Joseph SingerSolegreen Ltd
2019
Gal BoginSolegreen Ltd
2019

Entity Summary

D-Pharm LTD., a drug-development company, focuses on the development of drugs for the treatment of central nervous system conditions. D-Pharm LTD. was founded in 1993 and is based in Rehovot, Israel. D Pharm operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange.D Pharm LTD (DPRM) is traded on Tel Aviv Stock Exchange in Israel and employs 11 people.

D Pharm LTD Leadership Team

Emanuel Kahane, IR Contact Officer
Tamar Kfir, Director
Ofir Shachaf, Director
Irit Kaufman, Independent Director
David Grossman, Chairman of the Board
Itschak Shrem, Chairman of the Board
Aharon Schwartz, Executive Chairman of the Board
Golan Bitton, CEO, Director
Ronen Rosenbloom, Director
Nir Zvi, Director
Ofra Yamin, VP of Fin. and HR
Yaron Meyer, General Counsel, Secretary
Assaf Segal, Director
Ofer Gonen, Director
Joshua Levine, Director
Anat Benish, External Director
Sagi Tamir, External Director
Yossi Hatan, Vice President - Finance
Gilad Rosenberg, Vice President Clinical Development
Sigal Gefen, External Director
Eli Cohen, Director
Alexander Kozak, Co-Founder, CEO and Pres
Zohara Ran, Independent Director

Stock Performance Indicators

Current Sentiment - DPRM

D Pharm LTD Investor Sentiment

Macroaxis portfolio users are insensible in their opinion about investing in D Pharm LTD. What is your opinion about investing in D Pharm LTD? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

D Pharm Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Freeport McMoRan and Hudbay Minerals. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
See also Investing Opportunities. Please also try Price Transformation module to use price transformation models to analyze depth of different equity instruments across global markets.
Search macroaxis.com